ERBB2 and breast cancer: The median OS for patients by molecular subtype was 86 months (IQR: 31–60 months) for HR+/HER2‐ breast cancer, not reached (IQR: 39–67 months) for HER2+, and 18 months (IQR: 9–21 months) for TNBC (Figure 2C).